ACC 2023: Late-Breaking Science Video Collection
Published: 06 March 2023
-
Views:
6155 -
Likes:
7
-
Views:
6155 -
Likes:
7
-
1m 17sPart 5 | Session 1 Dr Akowuah: Cardiovascular Research & Message for Early-Career Researchers
-
1m 22sPart 5 | Session 2 Dr Kini: Asking Questions & Her Motivation to Do Research on Plaque
-
5m 29s
-
1m 21sPart 5 | Session 4 Dr Verma: Passion for Electrophysiology & His Advice For Young Researchers
-
3m 33s
-
31sPart 5 | Session 6 Dr Hahn: Innovative Areas of Cardiovascular Science in 2023
-
1m 33sPart 5 | Session 7 Dr Forrest: Structural Heart Innovations and Advice to Young Researchers
-
16m 12sPart 1 | Session 1 The CLEAR-Outcomes Trial with Dr Harriette Van Spall & Dr Steven Nissen Harriette Van Spall, Steven E Nissen
-
16m 24sPart 1 | Session 2 The REVIVED-BCIS2 Viability Study with Dr Harriette Van Spall, Dr Divaka Perera & Dr Peter O'Kane Harriette Van Spall, Divaka Perera, Peter O’Kane
-
14m 3sPart 1 | Session 3 The BETTER-CARE HF Trial with Dr Harriette Van Spall & Dr Amrita Mukhopadhyay Amrita Mukhopadhyay, Harriette Van Spall
-
17m 32sPart 1 | Session 4 The COORDINATE-Diabetes Trial with Dr Harriette Van Spall, Dr Neha J Pagidipati & Dr Christopher B Granger Christopher B Granger, Harriette Van Spall, Neha Pagidipati
-
12m 7sPart 1 | Session 5 The BIOVASC Trial with Dr Harriette Van Spall & Prof Roberto Diletti Roberto Diletti, Harriette Van Spall
-
5m 59sPart 2 | Session 1 Statins to Protect Heart During Cancer Treatment: The STOP-CA Trial Marielle Scherrer-Crosbie
-
5m 38sPart 2 | Session 2 RENOVATE-COMPLEX-PCI: IVUS Vs OCT Optimisation in Complex PCI Joo-Yong Hahn
-
8m 1sPart 2 | Session 3 Effect of Evolocumab on Coronary Plaque Morphology: The YELLOW III Study Annapoorna Kini
-
5m 41sPart 2 | Session 4 Mini-Thoracotomy Vs Sternoctomy for Degenerative Valve Disease: The UK Mini-Mitral Study Enoch Akowuah
-
3m 46sPart 2 | Session 5 TAVR in Low-Risk Aortic Stenosis Patients: 3-Year Results From the Evolut Low Risk Trial John Forrest
-
5m 53sPart 2 | Session 6 Pulsed Field Ablation in Persistent Atrial Fibrillation Patients: The PULSED AF Trial Atul Verma
-
3m 44sPart 2 | Session 7 MK-0616: Oral PCSK9 inhibitor In Hypercholesterolemia Patients Christie Ballantyne
-
5m 21sPart 2 | Session 8 Evaluation of the Mechanism of Benefit for Dapagliflozin in HFpEF Barry Borlaug
-
3m 7sPart 2 | Session 9 BMAD Trial: μCor in Ambulatory Decompensated Heart Failure John Boehmer
-
5m 44sPart 2 | Session 10 The STELLAR Phase II Trial: Sotatercept in Patients With Pulmonary Arterial Hypertension Marius Hoeper
-
8m 2sPart 2 | Session 11 Inflammatory Risk from Statin-Treated Patients: Findings from PROMINENT, REDUCE-IT and STRENGTH Paul M Ridker
-
33m 36sPart 3 | Session 1 ACC.23 Late-breaking Science Wrap Up Nicolas M Van Mieghem, Joost Daemen
-
22m 4sPart 3 | Session 2 What's Hot at ACC.23? Late-breaking Science Preview Nicolas M Van Mieghem, Joost Daemen
-
16m 22sPart 4 | Session 1 Interventional Late-breaking Highlights with Dr Mirvat Alasnag & Dr Khaled Al-Shaibi Mirvat Alasnag, Khaled Al-Shaibi
-
5m 34sPart 4 | Session 2 Lipid Management & the CLEAR Trial with Dr Erin Michos Erin D Michos
-
17m 7sPart 4 | Session 3 Obesity Management Strategies in 2023 with Dr Harold Bays Harold Bays
Overview
Our regular review series View from the Thoraxcenter, hosted by Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) provides a critical analysis of the late-breaking and featured science results and spotlights impactful data.
For a deeper look into the key clinical trial data revealed at ACC 23, Dr Harriette Van Spall (McMaster University, Hamilton, CA) interviews the principal investigators in her regular Late-Breaker Discussion Series.
For short, concise coverage of the key data revealed, our accessible Expert Interviews were conducted with select faculty, focussing on the results, applicability and impact on future research.
More from this programme
Part 1
Late-Breaker Discussion Series
Host, Dr Harriette Van Spall is joined by principle investigators for discussion on selected late-breaking trials.
Part 2
Expert Interviews
Part 3
View from the Thoraxcenter
In these concise episodes of View from the Thoraxcenter, Prof Nicolas Van Mieghem and Dr Joost Daemen (Thoraxcentre, Erasmus MC, Rotterdam, NL) offer their thoughts on the top late-breaking trials that will be presented at ACC 2023.
Part 4
Highlights Reviews
Part 5
Behind the Heart
Watch our Behind the Heart series to learn more the personal perspectives from the investigators behind top trials in cardiovascular science.
About the episode
Dr B Hadley Wilson (Carolinas Medical Center, US), the newly elected president of the American College of Cardiology, joins us to talk about ACC.23 with WCC.
In this video, Dr Wilson takes us through the highlights from the ACC.23 Annual Scientific Session & Expo and reflects on the role of medical meetings in the pre- and post-pandemic world.
We also delve into the challenges and opportunities that lie ahead for the ACC, as well as some of the key educational opportunities available for the cardiology community. Dr Wilson also offers his commentary on the most significant late-breaking trials from ACC.23, including CLEAR-Outcomes, STOP-CA, BIOVASC, and more.
Faculty Biographies
B Hadley Wilson
Dr B Hadley Wilson, is the president of the American College of Cardiology (2023-2024). Dr Wilson is an interventional cardiologist and executive vice chair at Sanger Heart and Vascular Institute/Atrium Health in Charlotte, North Carolina. He is also a Clinical Professor of Medicine at Wake Forest University School of Medicine. Dr Wilson is a graduate of Davidson College and Duke University School of Medicine, where he earned honors. He completed his internal medicine training at Vanderbilt University, where he served as chief resident. After his cardiology fellowship, he joined Sanger Heart and Vascular Institute as an interventional cardiologist and held various leadership roles, including director of the catheterization laboratory and chief of cardiology, for over 15 years.
With almost 25 years of membership in the American College of Cardiology (ACC), Dr Wilson has demonstrated his commitment to the field through his numerous leadership positions, including…
Comments